Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)

N/ANot Yet RecruitingNCT06141538

First Affiliated Hospital Xi'an Jiaotong University500 enrolled

Overview

This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.

The researcher-initiated clinical cohort study is a national multicenter, retrospective-prospective study of non-valvular atrial fibrillation patients with intracardiac thrombus, based on molecular biology and multi-omics analysis. The study aims to analyze the changes in the body's immune status, metabolic status, and host microbiome community structure, as well as to analyze the factors that influence the responsiveness of intracardiac thrombus to anticoagulant therapy. The study also evaluates the occurrence of adverse events related to anticoagulation in these patients.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Atrial Fibrillation Intracardiac Thrombus

Interventions

Observational; No Interventions were given.OTHER

Observational; No Interventions were given.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years old, age ≤80 years old * Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter * Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy Exclusion Criteria: * Echocardiography confirmed valvular heart disease * Contraindications to anticoagulants * Patients with the previous history of hemorrhagic stroke * Low platelet count or functional platelet defects * Congenital or acquired coagulation or bleeding disorders * Abnormal liver function (liver enzymes \>2 times the upper limit) * Renal failure (endogenous creatinine clearance \<30ml/min) * Surgery was planned within the intended study time or had been operated within 30 days before the study * Other comorbidities that can cause bleeding, such as tumors * Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators * Patients are currently participating in other clinical studies

Locations (1)

First Affiliated Hospital of Xian Jiantong University

Xi'an, Shaanxi, China